St. Jude Medical and Nanostim

St. Jude's Nanostim leadless pacemaker--Courtesy of St. Jude Medical

The deal: St. Jude Medical scoops up Nanostim
The price tag: $123.5 million

Why it matters: With its purchase of Nanostim last fall, St. Jude ($STJ) became the owner of the only leadless cardiac pacemaker to hit the market until now. Nanostim's leadless pacemaker is about as big as a AAA battery, less than 10% of the size of a regular pacemaker, and it had just obtained CE mark approval when the deal went through. St. Jude planned ahead for this one. It first began courting Nanostim in 2011 as an investor, with an option to buy the California company. Pacemaker implants are a sluggish sector, and the wireless option could spark new growth and also reduce complications by eliminating the need for wires to connect the device to the heart. Earlier this year, St. Jude announced the first Nanostim implant in a U.K. patient. In February, it implanted the device in its first U.S. patient in the start of what will be a pivotal trial for FDA approval.

For more:
St. Jude puts the Nanostim leadless pacemaker in its first U.S. patient
St. Jude Medical grabs Nanostim for $123.5M, gaining CE marked leadless pacer
Nanostim reports early human success with leadless pacer

St. Jude Medical and Nanostim